Clinical Trial Update: A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and immunogenicity of the MRKAd5 Gag/Pol/Nef HIV vaccine in healthy adults, with results posted after complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MRKAd5 Gag/Pol/Nef vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1, HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2011-07-07